## SYK: Stryker Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -5.1% below STRENGTH zone (4.0-10.0%); PEG 1.86 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($338.11)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Investment Management Corp of Ontario Decreases Position in Stryker Corporation $SYK**
- Source: MarketBeat | 20251210T123719 | Neutral | Relevance: 99%
-  Investment Management Corp of Ontario significantly reduced its stake in Stryker Corporation by 25% during the second quarter, selling 4,427 shares. Despite this, other institutional investors have bought new positions or increased their holdings in Stryker. The company maintains an average analyst rating of "Moderate Buy" with an average price target of $433.78, and recently exceeded earnings estimates while reporting strong revenue growth.

**2. 3 Reasons Investors Watch Stryker (SYK)**
- Source: TradingView | 20251210T040903 | Somewhat-Bullish | Relevance: 99%
-  Stryker (SYK) has seen a 9% loss in shares over the past six months, prompting investors to assess its potential. The company exhibits strong organic revenue growth averaging 10.2% annually, indicating a solid core business. With $24.38 billion in revenue, it benefits from economies of scale, giving it significant negotiating leverage, and has shown outstanding long-term EPS growth of 13.1% annually over five years, confirming profitable expansion.

**3. Stryker declares an $0.88 per share quarterly dividend**
- Source: Bakersfield.com | 20251211T130847 | Bullish | Relevance: 99%
-  Stryker (NYSE:SYK) announced a quarterly dividend of $0.88 per share, representing a 4.8% increase from the prior year and previous quarter. This dividend is payable on January 30, 2026, to shareholders of record by December 31, 2025. The company's CEO, Kevin Lobo, expressed confidence in their strong financial performance and commitment to capital allocation priorities.

**4. Stryker Corporation Declares Quarterly Dividend, Payable on January 30, 2026**
- Source: marketscreener.com | 20251211T152833 | Bullish | Relevance: 99%
- Stryker Corporation announced a quarterly dividend of $0.88 per share, payable on January 30, 2026, to shareholders of record as of December 31, 2025. This dividend represents a 4.8% increase compared to the previous year and quarter. The medical equipment company continues its commitment to returning value to shareholders.

**5. State Street Corp Increases Stake in Stryker Corporation $SYK**
- Source: MarketBeat | 20251209T134902 | Somewhat-Bullish | Relevance: 99%
-  State Street Corp increased its stake in Stryker Corporation (NYSE:SYK) by 1.0% during the second quarter, now owning 3.91% of the company's stock valued at over $5.9 billion. Other institutional investors have also adjusted their positions, and analysts generally rate Stryker as a "Moderate Buy" with an average target price of $433.78. Recent insider transactions show executives selling shares.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $420 | $455 | -8% |
| 2025-11-14 | Truist Securiti | $400 | $392 | +2% |
| 2025-11-14 | Wells Fargo | $456 | $452 | +1% |
| 2025-11-14 | Needham | $448 | $448 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | main | Buy |
| 2025-11-14 | Truist Securiti | main | Hold |
| 2025-11-14 | Wells Fargo | main | Overweight |
| 2025-11-14 | Needham | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($34.68M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (+0.8%)
- Blackrock Inc.: 7.0% (+0.4%)
- JPMORGAN CHASE & CO: 6.2% (+95.3%)
- Greenleaf Trust: 4.3% (-0.3%)
- State Street Corpora: 3.9% (-0.1%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.4% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $35M sold (6 transactions in 90 days).
3. Long-term trend broken: trading 6.2% below SMA200.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.86 elevated, pricing in significant growth expectations. Forward P/E 23.6x stretched relative to 10% growth. Balance sheet: $1.4B free cash flow. Insider selling cluster ($34.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $135.0B |
| Beta | 0.90 |
| 52W Range | $329.16 - $406.19 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.86 |
| Forward P/E | 23.6 |
| Current P/E | 26.1 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -2.7% to -5.1% (-2.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.1pp (needs >4.0% for momentum thesis). AM_20 at -3.0% indicates price below own 20MA trend. Below SMA200 (0.94x), long-term trend not supportive. MACD histogram bearish (-1.63), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -5.13% (CS: 11) | Weak |
| RSI_14 | 39.1 | Neutral |
| MACD Histogram | -1.63 | Bearish |
| vs SMA20 | 0.970x | Below |
| vs SMA50 | 0.962x | Below |
| vs SMA200 | 0.938x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $352.97
- **Stop Loss:** $338.11 (4.2% risk)
- **Target:** $367.83 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 92
- **Position Value:** $32,473.24
- **Portfolio %:** 32.47%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-01-27 (Est: $4.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.13 | $3.19 | +1.9% |
| 2025Q2 | $3.07 | $3.13 | +1.9% |
| 2025Q1 | $2.73 | $2.84 | +4.0% |
| 2024Q4 | $3.87 | $4.01 | +3.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*